Sarepta Therapeutics Inc
Most Recent
Why Is Sarepta Therapeutics Tanking Today?
Yesterday, Sarepta Therapeutics received a response from the FDA that raised concerns about its golodirsen new drug application.
Amarin’s Q2 Earnings and Robust 2019 Outlook
Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.
Analysts Are Optimistic about Sarepta Therapeutics in March
Wall Street analysts expect a potential upside of 77.04% for Sarepta Therapeutics (SRPT) based on the company’s closing price on March 27.
Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?
Wall Street analysts have projected Sarepta Therapeutics’ revenues to be $395.55 million, $611.37 million, and $1101.00 million, for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
How Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
A Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Do Analysts See Any Upside for bluebird bio Stock?
In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.
Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Sage Therapeutics: Analyzing New Product Candidates
The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.
Sage Therapeutics’ Operational Performance
In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
An Investor’s Overview of Sarepta Therapeutics
Sarepta Therapeutics’ revenues are forecast to be $302.13 million in 2018 and $430.37 million in 2019, up from $154.58 million in 2017.
Analyzing Sarepta’s Product Pipeline
Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.
Recent Developments for Portola Pharmaceuticals
In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy.
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Analyzing PTC Therapeutics’ Performance in September
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Sarepta Therapeutics Has Returned 169.97% Year-to-Date
Sarepta Therapeutics (SRPT) has returned 169.97% YTD. In the second quarter, its EPS was -$0.43, surpassing the consensus estimate by $0.46.
Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
What Sarepta Therapeutics’ Valuation Trend Indicates
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter compared to a net loss of $63.05 million in Q2 2017.
Exondys 51 Growth Bodes Well for Sarepta’s Top Line
For fiscal 2018 and fiscal 2019, Sarepta is expected to generate revenues of $302.25 million and $428.48 million, respectively.
A Look at Incyte’s Valuation on August 22
On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
What Analysts Recommend for Ionis after Q2 2018
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.
How Ionis’s Q2 2018 Earnings Trended
Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
Analysts Have Mixed Opinions about Ionis
Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.
NASDAQ All-Stars
The starting lineup for the Nasdaq All-Stars features names such as MongoDB (NASDAQ: MDB), Etsy Inc. (NASDAQ: ETSY), and Netflix Inc. (NASDAQ: NFLX).
Why Tonix Pharmaceuticals Stock Soared Today
Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.
What’s behind Gemphire Therapeutics’ Stock Price Rise
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.
Why Summit Therapeutics Stock Crashed Yesterday
On June 27, Summit Therapeutics announced that its phase two PhaseOut DMD trial failed to meet its primary endpoint.
What Analysts Think of PolarityTE and Its Peers
In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.
Why Investors Are in a Frenzy over Sarepta Stock in June
On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial.
A Look at Sarepta’s Exondys 51 Commercialization Efforts
By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders.
Versartis Stock and Its Consistent Rise in the Week Ended June 8
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.
Analysts’ Ratings for Sarepta Therapeutics and Peers in April
Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.
How BioMarin Pharmaceutical Performed in 4Q17 and 2017
In 4Q17, BioMarin Pharmaceutical (BMRN) generated revenue of $358.3 million, compared with $300.1 million in 4Q16.
Why Spark Therapeutics Stock Rose in the Week Ended March 29
On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.
Sarepta Awaiting Approval for Exondys 51 in Europe
European market approval On December 20, 2016, Sarepta Therapeutics (SRPT) announced that the MAA (marketing authorization application) for Exondys 51 (eteplirsen) for Duchenne muscular dystrophy (or DMD) patients above four years of age with mutations amenable to exon-51 skipping was accepted by the EC (European Commission). After receiving initial feedback from the EC related to […]
Confirmatory Studies May Expand Uptake of Exondys 51
Demand trends Sarepta Therapeutics (SRPT) reported that by the end of 3Q17, all Tier 1 and Tier 2 sites, which will be treating around 75% of DMD (Duchenne muscular dystrophy) patients with mutations amenable to exon-51 skipping, had submitted start forms for Exondys 51 (eteplirsen). The company has also witnessed an increase in start forms submitted […]
Xenoport Surges on Takeover Bid and Outperforms the Market
On May 23, the Dow Jones Industrial Average remained unchanged while the SPDR S&P 500 ETF (SPY) went down by 0.1%. The SPDR S&P 500 ETF rose by 0.75 YTD.
IHI Bucks the Downward Trend for the Week Ending May 6
For the week ending May 6, the iShares US Medical Devices (IHI) outperformed markets and other biotech ETFs with a return of 0.1%.
IBB Returns to Positive: How Did Its Holdings Perform?
The iShares NASDAQ Biotechnology ETF followed the market trend and gained 1.1% after a five-day losing streak, a positive beginning for the month of May.
XBI Had the Best Trading Day Year-to-Date
The SPDR S&P Biotech ETF (XBI) witnessed the best trading day year-to-date in terms of gains on April 6, 2016.
R&D Failure Is the Principal Risk Faced by BioMarin
The biotechnology industry operates in a dynamic environment embedded with a high-risk business model. The principal risk faced by the industry is R&D failure.
BioMarin’s Pipeline for Duchenne Muscular Dystrophy
There are four drugs in the pipeline targeting Duchenne muscular dystrophy. The company holds Kyndrisa, BMN044, BMN045, and BMN053 for the indication of DMD.
Overview of BioMarin: History and Product Portfolio
Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.
Chimerix Falls 80% following Phase 3 Trial of Brincidofovir
Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.
IBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.
IBB Leads Biotech ETFs with Rise of 3.1%
Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.
Radius Continued to Fall despite Positive Data on Osteoporosis
Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.